Read More

Curis Highlights Publication Of Manuscript In Peer-Reviewed Journal ‘Gastroenterology’ On Role Of Protein Kinase IRAK4 In Pancreatic Ductal Adenocarcinoma And Preclinical Efficacy Of Co.’s Emavusertib In Combo With Checkpoint Immunotherapy

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a manuscript has been published in the peer-reviewed journal

CRIS

Read More

Earnings Preview For Curis

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an earnings per share (EPS) of $-0.13.

CRIS

Read More

Curis Earnings Preview

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that Curis will likely report an Earnings Per Share (EPS) of $-0.13

CRIS